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ABSTRACT
Breast tumours are heterogeneous and contain populations of cells with stem-like
qualities that are characterized by long term self-renewal capability and the ability to
generate more differentiated progeny. This model for carcinogenesis carries significant
clinical implications as cancer stem-like cells have enhanced protective mechanisms that
make them resistant to conventional therapies. Designing treatment options to target this
aggressive population requires an understanding of the mechanisms regulating their
growth and fate decisions, including cell cycle regulation. The protein Spy1 is an atypical
cyclin that enhances cell proliferation and overrides senescent barriers. Spy1 has
demonstrated roles in maintaining stemness in the brain and is elevated in human breast
carcinoma. This study demonstrated that Spy1 is a driver in the population of stem-like
cells across a number of different breast cancer cell lines. The findings in this study may
have clinical implications toward targeted approaches in the treatment of breast cancer.
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INTRODUCTION
I.

A brief overview of mammary gland development
Development of the human mammary gland is a dynamic process undergoing a

series of changes including stages of growth, puberty, pregnancy, lactation and
regression1. The mammary gland is a secretory organ that is responsible for the
production of milk. It is comprised of two tissue compartments, the epithelium and the
stroma1. The epithelium consists of mammary ducts that transport milk and alveolar cells
that produce milk1. The stroma is a region of connective tissue that is also referred to as
the mammary fat pad1. The stroma hosts a wide variety of cell types including
adipocytes, fibroblasts, blood cells and neurons1. As puberty commences, estrogen and
progesterone are produced in a cyclical manner causing a stimulation of ductal outgrowth
and side branching1. During pregnancy, prolactin and placental hormones direct the
proliferation and development of the alveolar compartment preparing the gland for milk
secretion2. In pregnancy, luminal secretory cells functionally differentiate to produce
milk3. Surrounding these secretory cells is a casing of specialized contractile
myoepithelial cells that aid in milk delivery3. This network of ducts and alveoli is
encased by the stroma, acting as a supporting structure for the epithelial components of
the mammary gland3. When lactation ceases, the loss of suckling and the resulting loss of
the stimulatory prolactin signal initiates a process called involution4. Involution is
characterized by massive cell death of luminal cells and remodels the mammary gland to
a state of simple ductal structure that resembles the gland pre-pregnancy4. Subsequent
pregnancies will initiate a new round of alveolar proliferation, maturation and lactation 4.
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The profound expansion of the mammary epithelium following successive rounds of
pregnancy implicates a stem cell population with extensive regenerative capacity5.
Stem cells are characterized by the ability to self-renew, giving rise to more stem
cells, and by the ability to produce the multitude of differentiated cells that comprise the
mammary epithelium5. Experimentally, these stem cells can be identified at the molecular
level by a number of markers (e.g., cell-surface proteins)6-7, and by gene expression
profiles8-9, as well as functional assays (e.g., enzymatic activity assays, etc.)10, to be
further elucidated below.
II.

The mammary epithelium is organized into a hierarchy
The concept of a self-renewing and bipotent mammary stem cell (MaSC) was first

introduced by Daniel et al. through pivotal transplantation experiments in mice and rats;
their work revealed that the structure of the mammary gland can be recapitulated from
serially transplanted random fragments of the epithelium11. Since then there is increasing
evidence to support the presence of a differentiation hierarchy in the adult mammary
gland7,12-18. Mammary epithelial transplant experiments have successfully demonstrated
that specific cell populations are capable of regenerating a fully functional mammary
gland16-17,19. These experiments take advantage of the fact that the epithelial ducts in a 3
week old mouse are confined to the most proximal region of the mammary fat pad; the fat
pad can subsequently be cleared through a process of de-epithelialization in which the
original epithelial ducts are removed1. Cell populations isolated based on their differing
cell surface marker expression can then be transplanted into the cleared fat pad where
they will be exposed to the native growth factors and hormone environment20. Kordon et
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al. utilized experiments involving the transplantation of random fragments of the
mammary epithelium marked with the mouse mammary tumour virus (MMTV) to
highlight the regenerative capability of stem cells within the mammary gland21. Serial
transplantations of clonally derived outgrowths were able to regenerate the functional
mammary gland in its entirety21. It has been established that not all of the different cell
types found within the mammary epithelium are capable of successfully regenerating a
functional mammary gland16-17,19. For example, cells negative for various lineage markers
(Lin-) and positive for select integrins (ex. CD29/integrin Beta1 and various Cluster of
Differentiation or CD proteins) have been shown to have stem-like properties19.
Shackleton et al. demonstrated through transplantation experiments that only single cells
from the Lin-CD29highCD24+ population were capable of regenerating a fully functional
mammary gland; cells within this population had properties of multipotency and the
ability to self renew, both of which are defining characteristics of MaSCs19. MaSCs can
divide asymmetrically22. Asymmetric division results in a daughter cell identical to the
MaSC, functioning as a mode of self-renewal that preserves the stem cell population as
well as produces another daughter cell, referred to as a progenitor cell, which can
eventually become a more differentiated cell type23. Bipotent progenitors can give rise to
the cell types that define the mature epithelium of either the luminal or myoepithelial
lineage (Figure 1)24-25. This intermediate bipotent progenitor can differentiate towards the
luminal lineage that eventually produces the ductal cells that comprise the inner lining of
the ductal network and the alveolar cells that form the milk producing alveolar structures
characteristic of pregnancy24-25. A bipotent progenitor can also differentiate towards the
myoepithelial lineage24-25; the fully differentiated myoepithelial cells form a matrix

3

Figure 1. Schematic of differentiation hierarchy within the mammary epithelium
Mammary stem cells (MaSCs) can self-renew to produce an identical stem cell. MaSCs
can also give rise to the cell types that define the mature epithelium of either the luminal
or myoepithelial lineage through a common or bipotent progenitor25. This intermediate
progenitor can differentiate towards the luminal lineage that eventually produces the
ductal cells that comprise the inner lining of the ductal network and the alveolar cells that
form the milk producing alveolar structures characteristic of pregnancy1,3. During
pregnancy, the alveolar progenitor may demonstrate bipotency25. A common progenitor
can also differentiate towards the myoepithelial lineage eventually forming fully
differentiated myoepithelial cells. Myoepithelial cells form a matrix enveloping luminal
secretory cells and aid in milk delivery due to their contractile nature1,3. Figure adapted
from Visvader 200925.
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enveloping luminal secretory cells and aid in milk delivery due to their contractile
nature3,24.
III.

Stem cells have defining characteristics
Stem cells are defined by the ability to self-renew and give rise to progeny that

can differentiate into the many cell types that comprise a mature gland23. The ability to
self-renew is indicative of a stem cell’s high proliferation potential and contribution to
organogenesis26. The ability to self-renew is also critical for maintaining the mature adult
gland and in some tissues contributes to repair upon insult or injury to part of the tissue2729

. MaSCs are critical for normal organ development, the maintenance of tissue

homeostasis, and the regeneration of a functional mammary gland during successive
reproductive cycles1,5,30. Stem cells are also defined by the ability to differentiate; this
multipotent nature allows for the production of the variety of differentiated cell types that
contribute to the functionality of the mature gland5-6,30. Stem cells have active antiapoptotic pathways and telomerase activity that contribute to their long-lived nature31-34.
Consequently, stem cells have more exposure to damaging agents with the risk of
acquiring mutations and have developed mechanisms to increase their resistance to
various damaging agents30,32,35. One mechanism to counteract this risk is the increased
expression of membrane transporter proteins, such as P-glycoproteins or breast cancer
resistance proteins36-37. Increased membrane transporter activity serves to protect stem
cells from toxic agents by pumping potential toxins out of the cells36-37. It has also been
suggested that membrane transporters may prevent stem cells from being subjected to
differentiation cues38. Good et al. demonstrated in Dictyostelium that transporters
function to exclude various differentiating factors, helping the stem cells remain in an
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undifferentiated state38. In addition, stem cells are able to grow in anchorage independent
conditions allowing for migration and homing to distant sites30,39-42.
Stem cells are able to divide symmetrically and asymmetrically (Figure 2)23.
Symmetric division involves the production of two daughter cells identical to the parent
stem cell23. Asymmetric division occurs when the parent stem cell produces one daughter
stem cell and one differentiated cell23. Symmetric cell division provides a mechanism for
stem cells to rapidly expand in number during critical times, such as in specific
developmental time periods or in response to injury26-29. It has been suggested that
asymmetric cell division may serve as a mechanism for maintaining appropriate numbers
of progeny23. Investigative studies into pathways regulating self-renewal decisions have
revealed a role for the Notch transmembrane receptor proteins43. In mammals, the Notch
family consists of four homologues (Notch 1 to 4)44-47. Notch proteins interact with both
surface bound and secreted ligands (Delta, Delta-like, Jagged 1 and 2)48, and subsequent
Notch signaling is modulated by members of the fringe family49. Notch receptor
activation involves cleavage events mediated by proteases of the ADAM (a disintegrin
and metalloproteinase) family in addition to an intramembrane cleavage event mediated
by presenilin48,50. The Notch intracellular domain then translocates to the nucleus where
it can regulate gene expression of several downstream targets by interacting with a
transcription factor complex comprised of C promoter binding factor (CBF), Suppressor
of Hairless and Lag-148. Activation of the Notch pathway regulates cell fate51-53. For
example, over-expression of activated Notch 4 in culture serves as a block for
differentiation of normal breast epithelial cells52. In vivo studies utilizing transgenic mice
over-expressing activated Notch 4 in the mammary gland revealed a failure to develop
6
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Figure 2. Modes of stem cell division
(A) Stem cells (S) can symmetrically divide producing two daughter cells identical to the
parent stem cell. (B) Asymmetric division occurs when the parent stem cell produces one
identical daughter stem cell and one differentiated progeny cell (P)23.
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normally; in addition, these mice eventually developed poorly differentiated mammary
tumours53.
IV.

Cell cycle mechanisms regulating cell populations
For a cell to create a new cell containing genetically identical material it must

undergo an orderly sequence of events in which it duplicates the cellular contents and
subsequently divides in two; this process of sequential duplication and division events is
known as the cell cycle54. The cell cycle is defined by distinct phases; S phase of the cell
cycle is when DNA replication occurs through chromosome duplication and M phase is
when mitosis and cytokinesis occur resulting in nuclear and cytoplasmic division
respectively54. Gap phases, G1 and G2, provide time delays to allow for cell growth and
the opportunity to monitor internal and external environmental conditions54. These gap
phases ensure conditions are favourable before committing to DNA replication. Critical
to the regulation of cell-cycle control are a type of protein kinases known as cyclindependent kinases (Cdks). The activities of Cdks are up-regulated and down-regulated
during cell cycle progression causing orderly changes in the phosphorylation of
intracellular proteins that regulate cell cycle events54-55. The most critical regulators of
Cdk activity are proteins known as cyclins54-55. Cyclins have structural and functional
similarities, and interact with Cdks through a conserved region of amino acids termed the
cyclin box57. Cdks depend on cyclin binding for initiation of protein kinase activity54-55.
In the absence of cyclin binding, a Cdk’s active site is blocked by the T-loop, rendering it
inactive58. Upon cyclin binding, the T-loop leaves the active site, resulting in the Cdk
becoming partially activated58. Complete activation of the cyclin-Cdk complex occurs
when a Cdk-activating enzyme (CAK) phosphorylates a threonine residue, causing a
8

conformational change59. The activated Cdk is then ready to phosphorylate target
proteins59. Various cyclin-Cdk complexes form throughout the distinct phases of the cell
cycle. For example, Cyclin D forms a complex with Cdk4 or Cdk6 in G1, Cyclin E forms
a complex with Cdk2 in G1/S, Cyclin A forms a complex with Cdk2 or Cdk1 in S, and
Cyclin B forms a complex with Cdk1 in M55.
V.

Mechanisms regulating Cdk activity
Additional mechanisms serve to regulate Cdk activity throughout the cell cycle.

Phosphorylation of two amino acids found in the active site of the kinase, namely Thr14
and Tyr15, by the Wee1 protein kinase results in inhibition of Cdk activity54. Removal of
this inhibitory phosphorylation state by the Cdc25 phosphatase in turn increases Cdk
activity60. Binding of Cdk inhibitor proteins (CKIs) negatively regulates cyclin-Cdk
complexes61. One group of CKIs is called the Cip/Kip (Cdk inhibiting protein) family and
includes p27Kip1, p21Cip1 and p57Kip2. Structural studies revealed that the Cip/Kip CKIs
bind cyclin-Cdk complexes at the interface of the complex, obstructing the adenosine
triphosphate (ATP) region of the Cdk61. This in turn prevents activation by obstructing
proper folding of the catalytic cleft61.
VI.

MaSC quiescence
Adult stem cells are often found in a reversible state of cell cycle arrest termed

quiescence62-64. Characterized by relative inactivity and low division rates, quiescence
protects stem cells from damage to genetic material and prevents exposure to
differentiation signals62-64. Quiescence also serves as a protective mechanism to prevent
premature depletion of the stem cell population, preserving their long life span62-64.
9

Quiescence is controlled at the G1 phase of the cell cycle through the action of CKIs such
as p27Kip1, p21Cip1 and p57Kip2

65-67

. When a cell receives signals to proliferate or

differentiate, the actions of CKIs are inhibited, and the stem cell is free to re-enter the cell
cycle65-67. Shackelton et al. demonstrated that there is a population of label-retaining cells
found within populations enriched for MaSCs, suggesting a subset of quiescent cells19.
The mammary gland niche, or microenvironment of supporting cells and extracellular
elements found in the stroma, also plays a role in regulating MaSC activity3. It is
suggested that the mammary niche provides both positive and negative signals to
modulate MaSC activity68-69.
VII.

Atypical cell cycle regulators: Spy1

Xenopus Speedy was discovered through a screen for genes that displayed
resistance to a rad1 deficient strain of Schizosaccharomyces pombe when subjected to
UV or gamma irradiation70. An independent group also identified a novel protein, p33RINGO (Rapid Inducer of G2/M progression in Oocytes) that was structurally identical to
Xenopus Speedy71. p33-RINGO allowed for initiation of Xenopus oocyte maturation to
occur and down-regulation of endogenous p33-RINGO inhibited progesterone-induced
maturation71. Xenopus Speedy and the human homolog SpeedyA1 (Spy1) possess 40%
homology72. Spy1 is encoded by the SPDYA gene on chromosome 2 in humans73. Spy1
is a member of the Speedy/RINGO family of proteins and the defining feature of family
members is a conserved core region termed the Speedy/RINGO box that facilitates
interaction with Cdks73.
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Spy1 is capable of binding and activating Cdk1 (G2/M) and Cdk2 (G1/S) to allow
for progression through the cell cycle70-74. Spy1 does not display sequence homology to
cyclin proteins and activates Cdks in a unique manner74. Unlike classical cyclins, Spy1
activates both Cdk1 and Cdk2 independent of the well defined changes in Cdk
phosphorylation; Spy1 can activate Cdk1 and Cdk2 without the phosphorylation on
Thr161 and Thr160 respectively74. In addition, Spy1-Cdk complexes are less sensitive to
CKI inhibition mediated specifically through p21Cip1 74. Spy1 has direct interactions with
p27Kip1 to promote its degradation; Spy1-Cdk2 complex phosphorylates p27Kip1 at
Thr187, tagging it for proteasomal degradation and allowing for cell cycle progression to
occur72,75. Thus, Spy1 acts to enhance cell proliferation72. Spy1 is a nuclear protein with
peak expression in the G1/S phase of the cell cycle75. Therefore, Spy1 is an atypical cell
cycle regulator, operating in a manner different from cyclins.
Spy1 expression is found in a multitude of human tissues, cell lines, and
cancers76-80. Spy1 protein and RNA levels are tightly regulated during mammary gland
development, showing elevated expression in the proliferating virgin gland and
maintaining high levels throughout early pregnancy78. Spy1 levels decrease significantly
in the later stages of pregnancy when terminal differentiation of the gland occurs78.
Previous work has established a role for Spy1 in various cancers76,79-81. Spy1 protein
levels are elevated in multiple types of glioma and are associated with increasing tumour
grade80. Spy1 protein levels are also significantly elevated in many human breast cancers
and play a role in non-hodgkin’s lymphomas81. Recent work from the Porter laboratory
has established a role for Spy1 in maintaining stemness in the brain80. Spy1 overexpression disrupts neuronal differentiation and promotes neurosphere clonal growth80. It
11

was also demonstrated that Spy1 plays a role in maintaining symmetric division and selfrenewal of brain tumour-initiating cells (BTICs), which share many characteristics with
neural stem cells80.
VIII. The prevalence of breast cancer in Canada
In Canada, breast cancer is the most common cancer in women excluding nonmelanoma skin cancers and is the second leading cause of death82. Estimates project that
on average 24 400 Canadian women will be diagnosed with breast cancer in 201482.
Strikingly, this disease will claim the lives of approximately 14 Canadian women every
day82. The effects of this disease are both devastating and widespread. Over 99% of cases
affect women, suggesting a critical link between the development of the female
mammary gland and the incidence of this disease82. Although advances in earlier
detection, diagnosis and treatment have given hope to those diagnosed with this disease,
much work remains to be done in the fight against breast cancer. Breast cancer is an
extremely heterogeneous disease, with stark differences at both the histological and
molecular levels. Gene expression profiling has identified at least six different subtypes
of breast cancer8-9. The subtypes include luminal A or B, basal-like, claudin-low, human
epidermal growth factor receptor 2 over-expressing (HER2/ERBB2), and normal-breastlike (Table 1)8-9. It is hypothesized that the different subtypes may be reflective of
different cells of origin responsible for initiating tumour formation83-84. The different
subtypes may also reflect differences in mutational profiles8. There is controversy over
whether normal-breast-like is a distinct molecular subtype; this subtype accounts for less
than 10% of all breast cancers, typically is characterized by small tumours and has a
favourable prognosis85-86. Luminal cell differentiation is associated with luminal A and B
12

Table 1: Breast cancer subtypes
Classification

Receptor
status
ER+ PR+/HER2-

Ki67
status
low

Luminal B

ER+ PR+/HER2+

high

HER2

ER- PRHER2+

high

Basal

ER- PRHER2-

high

Claudin-low

ER- PRHER2-

low

Luminal A

Response to
therapy
often
chemotherapy
responsive
variable
chemotherapy
response,
endocrine
responsive
chemotherapy
responsive,
trastusumab
responsive
endocrine
nonresponsive,
variable
chemotherapy
response
low
chemotherapy
response

Potential cell of
origin
differentiated
luminal cells

Representative
cell line
MCF-7

differentiated
luminal cells

BT474

late luminal
progenitor

SK-BR-3

bipotent
progenitor/luminal
progenitor

MDA-MB-468

mammary stem
cell

MDA-MB-231
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subtypes; these subtypes are usually responsive to therapies and thus associated with
favourable patient outcome25,84,87-88. Breast cancers over-expressing HER2 also
exemplify luminal characteristics, although this subtype has poor patient survival
rates84,87-89. Basal breast cancers encompass 15-20% of all breast cancers, are
heterogeneous in nature, and are poorly differentiated90. Claudin-low breast cancers
characteristically have decreased expression of claudins, proteins involved in tightjunctions and cell-to-cell adhesion91. Another approach to stratifying breast cancers is
based on receptor status; breast cancers can be classified based on the presence or
absence of the estrogen receptor (ER), progesterone receptor (PR) and amplification of
the HER2/ERBB2 locus92-94. Stratification of breast cancers based on receptor status
allows prediction of a probable response to specific therapies and has improved
predictions of overall patient outcome89,92,94. The most aggressive tumours are classified
as triple negative, referring to the lack of expression of ER, PR, and HER2 and typically
respond poorly to treatment94. However, despite increases in predictability based on
receptor status of tumours, patient response to chemotherapy still varies substantially25.
Improving detection and treatment options for breast cancer patients ultimately requires a
complete understanding of the specific populations of cancer cells that actively drive
breast tumourgenic growth.
IX.

The cancer stem cell model
The cancer stem cell (CSC) model is based on a hierarchical model of tumour

development32. It suggests that only a small population of cells is capable of initiating
tumours and the vast majority of cells within a tumour are differentiated with limited
replicative potential32,95. The CSC model hypothesizes that deregulation of processes
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governing normal adult stem or progenitor cells results in malignant transformation of
this population of cells, allowing for them to drive tumour growth and progression32,95.
Clonal expansion of the stem and progenitor populations allows for the possibility of
accumulating additional genetic or epigenetic changes, resulting in complete malignant
transformation of these cells32,95. It is this dangerous population of CSCs that initiate and
drive tumour progression32,95. This is in contrast to the stochastic model of tumour
development, which argues all cells within a heterogeneous population have the capacity
to initiate a tumour32. Evidence for the existence of a CSC was solidified in 1994 by Dr.
John Dick in a leukemia model system96. This pioneering study revealed that cells
expressing a CD34+CD38- cell surface phenotype were leukemia-initiating cells; when
injected into severe combined immunodeficient (SCID) mice these cells were able to
form tumours that resembled the heterogeneous tumours found in acute myeloid
leukemia patients96. Evidence for the existence of CSCs in solid tumours was
demonstrated by the observation that not all cell types within breast tumours were
capable of initiating tumour growth when transplanted into immunodeficient mice97.
Breast cancer cells marked with the cell surface marker phenotype CD44+/high/CD24-/low
have stem-like properties and enhanced tumourigenic capacity97. CD24, also known as
heat specific antigen, is a glycosylphosphatidylinositol-anchored glycoprotein involved in
cell adhesion98. CD44 is a transmembrane glycoprotein involved in numerous cellular
processes such as cell migration, homing and adhesion99. Al-Hajj et al. isolated breast
cancer cells based on a CD44+CD24- phenotype from primary tumours and pleural
effusions of breast cancer patients and injected them into cleared fat pads of
immunocompromised mice97. As few as 100 CD44+CD24- cells formed tumours, whereas
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injection with over 10 000 CD44-CD24+ cells did not97. Numerous studies have provided
support for the concept that not all cells within a tumour are created equal in terms of
their tumour forming ability and capacity to recapitulate a heterogeneous tumour97,100-102.
Analysis of both normal stem cells and CSCs reveals many similarities in
important phenotypic characteristics30. Normal adult stem cells are slow-dividing and
long-lived, the latter an attribute which increases the risk of accumulating mutations to
serve as a target for transformation30. A normal adult stem cell is in part defined by its
ability to self-renew, a property CSCs may use to achieve uncontrolled proliferation and
tumourgenicity30. A CSC is able to differentiate into the multitude of cell types that
comprise a tumour, contributing to tumour heterogeneity30. Zucchi et al. showed that a
single LA7 cell derived from rat mammary adenocarcinoma was able to differentiate into
all the cell lineages found within the mammary gland102. Normal adult stem cells have
enhanced protective mechanisms against toxic insults; similarly, CSCs may be resistant
to damaging agents and may serve as one explanation for chemoresistance in clinical
settings30. Normal adult stem cells are typically anchorage-independent, with the ability
to survive and migrate to distant sites30. This feature may be exploited by CSCs to
achieve metastasis, or the development of a malignant growth at sites distant from the
primary tumour30. The CSC model for carcinogenesis carries significant clinical
implications, as this aggressive population of cells may be protected against the action of
conventional therapies and serve as a mechanism for relapse30,32,95.
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X.

Mammosphere culture as a tool to enrich for mammary stem, progenitor,
and breast CSCs
Epithelial cells depend on interaction or attachment to a substratum when cultured

to survive and proliferate; that is, normal epithelial cells are anchorage-dependent and
undergo apoptosis when unable to attach to a substratum39-42,103. The mammosphere assay
takes advantage of the observation that stem cells are able to grow in serum-free
suspension, which in vivo allows for migration and homing to distant sites30,104-105. Based
on the model of neurospheres (free-floating spherical structures enriched for neural stem
and progenitor cells)40, a culture system was developed that involved seeding human
mammary epithelial cells onto ultra-low attachment plates in order to enrich for cells able
to grow in anchorage-independent conditions106. Early mammosphere experiments
revealed that a small subset of cells are able to survive and proliferate in such conditions,
forming multicellular spheroids termed ‘mammospheres’106-107. Dontu et al. demonstrated
that mammospheres are enriched for bipotent progenitors eightfold over mammary cells
grown in anchorage-dependent conditions106. They further demonstrated that these
progenitors could differentiate into myoepithelial, ductal or alveolar cells106. When
subjected to 3 dimensional culture systems, progenitors were able to form complex
functional structures106. Self-renewal properties of the different cell types forming
mammospheres were also assessed through clonal assays in which mammospheres were
dissociated into single cell suspensions, re-plated, and tested for the ability to form
second generation spheres106. The results support the model of a MaSC undergoing
limited self-renewal divisions and giving rise to more differentiated progenitors106.
Microarray analysis revealed differences in the gene expression profiles of multipotent
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cells in secondary mammospheres compared to cells grown in conditions favouring
differentiation106. Genes expressed in mammospheres highly overlapped with genes
expressed in haematopoietic, neuronal and embryonic stem cells106. For example,
increased active TGF-beta signalling and increased expression of membrane transporter
proteins were found in mammospheres106. These characteristics are consistent with
previously established stemness attributes106,108. Thus, the mammosphere assay is a
reliable in vitro suspension culture system that allows for the study and enrichment of
mammary stem and progenitor cells.
XI.

Aldehyde dehydrogenase as a marker for normal and CSCs
The human aldehyde dehydrogenase (ALDH) superfamily encompasses 19

known putatively functional genes109-110. ALDH enzymes show multiple areas of
localization including in the cytosol, nucleus and mitochondria and vary widely in their
tissue and organ distribution111-113. The ALDH superfamily is a group of enzymes that
catalyze the oxidation of aldehydes to their corresponding carboxylic acids109-110,112.
Aldehydes are long-lived, highly reactive compounds with critical roles in normal
physiological responses, and with mutagenic and cytotoxic potential109,112. Aldehydes can
come from both endogenous and exogenous sources. Endogenous aldehydes are
generated through metabolic amino acid catabolism112, metabolism of vitamins and
steroids109-110, in addition to several other metabolic processes. Exogenous aldehydes can
be generated through biotransformation of xenobiotics and drugs, and are present in
smog, cigarette smoke and motor vehicle exhaust112. Therefore, ALDH enzymes play a
critical role in protecting cells from the possible detrimental effects of endogenous and
exogenous aldehydes112. It has been shown that the ALDH1 family (ALDH1A1, 1A2,
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1A3, 1L1, 1L2) are highly expressed in adult stem cells and CSCs and thus are used as
markers to characterize this distinct population10,

112

. To avoid pitfalls with enzyme

kinetics and immunoblotting methods which require lysis and endogenous release of
ALDH enzymes from cells114-115, the use of flow cytometry and fluorescent substrates for
ALDH1 allows for the study of ALDH1 activity in viable cells116-117. Storms et al.
developed an assay (Aldefluor® Assay) in which a fluorescent ALDH1 substrate,
BODIPY aminoacetaldehyde (BAAA) passively diffuses into intact, viable cells (Figure
3)117. ALDH1 will subsequently convert BAAA into the negatively charged product
BODIPY-aminoacetate (BAA-)117. BAA- is trapped inside the cell and consequently, cells
with high ALDH1 activity become highly fluorescent117. Use of cold assay buffer
prevents the ATP-binding cassette transporters from excluding the BAA- substrate out of
the cells10. To distinguish cells with high ALDH1 activity, populations in the top 10-20%,
populations are compared to a negative control utilizing diethylaminobenzaldehyde
(DEAB), a specific inhibitor of ALDH1117-119. The Aldefluor® Assay serves as a reliable
tool to identify cells with high ALDH1 activity in various human models118-120.
Cancer cells expressing high levels of ALDH activity have increased
tumourigenic capacity and demonstrate more stem-like characteristics compared to low
ALDH expressing cells118-119. Ginestier et al. used transplantation experiments to
demonstrate the highly tumourigenic nature of ALDH+ cells119. When 50 000 ALDHcells were transplanted into cleared fat pads of immunocompromised mice no tumours
developed; when 500 ALDH+ cells were transplanted tumours formed within a 40 day
time period119. Recent evidence suggests high activity of ALDH is associated with poor
prognosis in breast, bladder and prostate cancer patients119,121-122. Specific to breast
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Figure 3. Schematic of Aldefluor® Assay
The Aldefluor® Assay serves as a reliable tool to indentify cells with high ALDH
activity in various human models118-120. A fluorescent substrate for ALDH1, BODIPY
aminoacetaldehyde (BAAA), passively diffuses into intact, viable cells. ALDH1 will
subsequently convert BAAA into the negatively charged product BODIPY-aminoacetate
(BAA-). BAA- is trapped inside the cell and consequently, cells with high ALDH activity
become highly fluorescent. Use of cold assay buffer prevents the ATP-binding cassette
transporters from excluding the BAA- substrate out of the cells. To distinguish cells with
high ALDH activity, populations are compared to a negative control utilizing
diethylaminobenzaldehyde (DEAB), a specific inhibitor of ALDH1. Figure adapted from
Aldefluor® Assay Information Sheet (www.stemcell.com)
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cancer, a study analyzing the tumours of 577 patients revealed tumours positive for
ALDH have a significantly lower survival overall compared to patients with tumours
negative for ALDH119. It is important to note that ALDH can serve as a valid CSC
marker in tissue types that normally do not express high levels of ALDH123. Some of
these tissues include the breast, lung and colon123. However, tissues with normally high
levels of ALDH, such as liver and pancreas, are not suitable for this type of analysis123.
Perhaps the most established functional role of ALDH in cell populations is in the
retinoid signalling pathway. Retinoic acid (RA) has established roles in regulation of
gene expression, morphogenesis and development124-126. Retinol is oxidized by alcohol
dehydrogenase (ADH) into retinaldehyde; this is a reversible reaction112,124.
Retinaldehyde is then irreversibly oxidized into RA by ALDH1. RA is then free to bind
the retinoic acid receptor (RAR) mediating changes in gene expression and cell
differentiation124,127. The regulation of ALDH1 is controlled by a negative feedback
mechanism127. Another functional role for the ALDH superfamily is that of detoxification
and cellular protection109-112 and mutations and overall deficiencies in specific ALDH
enzymes are associated with disease states128-129. For example, mutations in ALDH1A2
are associated with spina bifida and ALDH2 with hypertension128-129. Using the
hematopoietic model, it was elegantly demonstrated that cells with high ALDH activity
were resistant to cyclophosphamide, a potent alkylating agent130. Using mouse models, it
was found that inhibiting the activity of ALDH1 caused a delay in the Go/G1 transition,
causing more hematopoietic stem cells to accumulate in Go compared to G2/S/M
phases131. This has powerful clinical implications. Targeting cells expressing high levels
of ALDH towards a more differentiated state may make them more sensitive to
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conventional therapies132. Similarly, targeting ALDH with DEAB can result in stem cell
expansion and can be used in applications like bone marrow transplants to improve
engraftment and patient survival131. More research is needed to investigate these potential
clinical avenues.
XII.

Cell surface marker expression can be used to isolate stem, progenitor
and breast CSCs

Another method researchers use to isolate MaSCs is separating sub-populations
based on the cell surface marker expression of the different cell types found within the
mammary epithelium17,19. Primary cell surface marker phenotype differs in the isolation
of mouse and human MaSC, although there are some instances of overlap25. For example,
MaSCs can express high levels of alpha 6 (CD49f) and/or beta 1 (CD29) integrins; mouse
MaSCs are enriched in the CD49fhighCD29high population whereas human MaSC are
enriched in the CD49fhighCD24-EpCAM-/low subset24-25. Beta 1 integrin is an important
extracellular matrix receptor that acts as a heterodimer with alpha and beta subunits133. A
role for beta 1 integrin has been established in the mammary gland, as it helps in
maintaining the stem cell pool and regulates the balance between basal and luminal
lineages through interactions with the stem cell environment133. Mammary tumours often
display decreased expression of both alpha 6 and beta 1 integrin134-135. It is suggested that
this down-regulation may allow for stem cells to detach from their native
microenvironment and migrate to other areas134-135. Researchers can use cell surface
marker expression in a combinatorial manner to isolate specific populations, sort these
populations based on fluorescence-activated cell sorting (FACS), and complete further
analysis for stemness properties both in vitro and in vivo97,137. As previously mentioned,
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human breast cancer cells marked with the cell surface marker phenotype
CD44+/high/CD24-/low have stem-like properties and enhanced tumourigenic capacity97,137.
Clarke et al. isolated cells based on a CD44+CD24-/lowLin- phenotype; injecting 200 of
these cells into cleared mammary fat pads of immunocompromised mice resulted in a
heterogeneous tumour whereas 20 000 cells negative for this phenotype did not137.
CD44+CD24-/lowLin- cells retained tumourigenic ability after serial passaging,
highlighting their ability to self-renew137. Al-Hajj et al. isolated breast cancer cells based
on a CD44+CD24- phenotype from primary tumours and pleural effusions of breast
cancer patients and injected them into cleared fat pads of immunocompromised mice97.
As few as 100 CD44+CD24- cells formed tumours97. Expression profiling of claudin-low
tumours reveals significant overlap with the CD44+CD24-/low breast cancer stem cell
population137. It has also been shown that cells with a CD44+CD24- phenotype exhibit
enhanced invasive properties that may contribute toward metastatic success and express
higher levels of anti-apoptotic proteins138. In vitro experiments revealed only the
CD44highCD24low fraction of the population are capable of forming mammospheres106.
Although it is well established in the literature that this cell surface phenotype enriches
for stem and progenitor cells, it likely does not solely contain only CSCs. Using this
phenotype in combination with other markers, such as ALDH+, may represent the most
aggressive CSC population119,132.
XIII. Using breast cancer cell lines as an in vitro model to study breast cancer
Breast cancer cell lines are a valuable in vitro tool for researchers to dissect
molecular mechanisms regulating the growth of breast cancer139. Neve et al. assessed the
molecular and biological similarities and differences between 51 breast cancer cell lines
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and primary human breast tumours140. Comparing genomic features, cell lines display the
same heterogeneity in copy number and expression aberrations as do primary tumours140.
In addition, cell line karyotypes remain relatively stable during extended culture
exposure140. Comparison between transcription profiles revealed that breast cancer cell
lines cluster into basal-like and luminal expression subtypes similar to primary
tumours140. However, tumours clearly resolve into two luminal subsets, which are less
apparent in cell lines140. Similarly, cell lines distinctly resolve into Basal A and Basal B
clusters, which are less apparent in primary tumours140. This may be due to the absence
of stromal interactions and/or the lack of native physiological interactions that exist in the
primary tumour microenvironment141. It has also been demonstrated that cell lines
contain functional CSCs142. Within 23 different breast cancer cell lines, the ALDH
positive population was sorted and subjected to analysis for stemness properties in vitro
and in vivo142. It was demonstrated that ALDH positive cells isolated from cell lines were
able to form mammospheres in culture, as well as form tumours when injected into
immunodeficient mice142. Overall the vast majority of breast cancer cell lines accurately
reflect the genomic and transcriptional characteristics of primary breast tumours and
provide a convenient tool for researchers to dissect mechanisms regulating breast cancer
initiation and progression140,142.
XIV. The role of Spy1 in breast cancer
A potential role for Spy1 in breast cancer first emerged when Zucchi et al. found
Spy1 as one of the 50 genes over-expressed in breast ductal carcinoma76. In vivo
transplantation experiments revealed that Spy1 over-expressing HC11 cells can
accelerate tumour formation in the mammary gland78. High Spy1 levels are found in
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aggressive breast cancers and down-regulation of Spy1 significantly inhibits breast
cancer cell growth79. It has also been shown that Spy1 protein levels are elevated in
human breast cancer cell lines79. Taking into account the established role of Spy1 in
breast cancer and maintaining stemness characteristics in other systems 80, I sought to
investigate the potential role of Spy1 in the CSC and progenitor populations in breast
cancer through a variety of reliable in vitro techniques. I hypothesize that Spy1 plays an
important role in the cell cycle regulation of breast cancer stem and/or progenitor
cells.
Objective 1: Determine a role for Spy1 in driving breast cancer stem and/or
progenitor cell growth. Various breast cancer cell lines were utilized as a model system
of breast cancer, reflective of some of the different subtypes of breast cancer. The
essentiality of the Spy1 protein was tested by manipulating levels (over-expression and
knock-down) of Spy1 by lentiviral infection. The effect on the relative stem cell
population was assessed through mammosphere assays and cell surface marker analysis
via flow cytometry.
Objective 2: Study the functional effect of Spy1 manipulation on the breast cancer
stem and/or progenitor cell populations. Using breast cancer cell lines as a model
system, Spy1 protein levels were manipulated by lentiviral infection and the relative
effect on the ALDH positive population was tested via flow cytometry analysis.
The CSC model for carcinogenesis carries significant clinical implications, as
cancer stem cells have enhanced protective mechanisms that make them resistant to
conventional therapies30,32,35. Designing treatment options to target this aggressive
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population requires an understanding of the mechanisms regulating their cell growth and
fate decisions. The cell cycle lies at the heart of these decisions, however there are large
gaps in knowledge regarding how this occurs. This research aims to resolve the key cell
cycle mediators, namely Spy1, in regulating specific breast cancer stem and/or progenitor
cell decisions, work that may be essential for advancing potential treatment options and
preventing patient relapse.
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MATERIALS AND METHODS
I.

Cell lines utilized

The human breast cancer cell lines used are listed in Table 2.
II.

Cell culture
MDA-MB-231 were maintained in Dulbecco's modiﬁed Eagle's medium

(DMEM) supplemented with 10% fetal bovine serum (FBS) (Gibco 12483) and 1%
penicillin and streptomycin (Gibco 1540). Once cells reached confluency, plates were
washed with sterile 1XPBS and 1mL of 0.05% trypsin (HyClone SH3023601) was added
to the plate for 3-4 minutes. Cells were then collected by centrifugation for 5 minutes at
1000rpm. Cells were cultured in a 5% CO2 environment.
MCF7s were maintained in DMEM supplemented with 10% FBS and 1%
penicillin and streptomycin. Once cells reached confluency, plates were washed with
sterile 1XPBS and 1mL of 0.05% trypsin was added to the plate for 3-4 minutes. Cells
were then collected by centrifugation for 5 minutes at 1000rpm. Cells were cultured in a
5% CO2 environment.
SK-BR-3 cells were maintained in McCoy’s 5A media (ATCC 30-2007)
supplemented with 10% FBS and 1% penicillin and streptomycin. Once cells reached
confluency, plates were washed with sterile 1XPBS and 1mL of 0.25% trypsin was added
to the plate for 3 minutes. Cells were then collected by centrifugation for 5 minutes at
1000rpm. Cells were cultured in a 5% CO2 environment.
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III.

Establishment of stable cell lines
10 000 cells per well were seeded in a 96 well plate containing 500µl of DMEM

media supplemented with 10% FBS for MCF7 and MDA-MB-231 cells and 500µl
McCoy’s 5A media with 10% FBS for SK-BR-3 cells, in the absence of penicillin and
streptomycin. Cells were grown overnight in a 5% CO2 environment. The following day
the growth media was changed to 500µl DMEM or McCoy’s 5A containing no serum or
antibiotics with 10µg/mL polybrene (Santa Cruz sc-134220). Cells were incubated for 20
minutes before virus was added to each well. The plate was gently rocked back and forth
and was returned to the incubator for approximately 24 hours. Multiplicity of infection
(MOI) was 10 and the virus titer for both control and shSpy1 was 107 titer units (TU).
After 24 hours, virus was removed by aspirating the media and replaced with fresh
growth media. The empty vector control (pLKO) and Spy1 knock-down (shSpy1)
contained puromycin selection and thus fresh media containing 10µg/mL puromycin
(Sigma-Aldrich P8833) was used to select for successfully infected cells and changed
every 2 days.
Over-expression of Spy1 (pEIZ-Spy1) or control (pEIZ) in MDA-MB-231 and
MCF7s were established by lentiviral infection using the same protocol as previous with
the exception of puromycin selection. Successful infected cells over-expressing Spy1
fluoresced green and this was monitored through fluorescence microscopy beginning 1
week after infection.
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IV.

Mammosphere assay
Cells were seeded into 6-well ultra low attachment plates at 50 000 cells/well

(Corning 07-200-601). Each well contained 2mL of mammary epithelial basal medium
(MEBM, Clonetics CC-3152) supplemented with mammary epithelial cell growth
medium (MEGM) Single Quots (Clonetics CC-4136), 20ng/mL human basic fibroblast
growth factor (Sigma-Aldrich F0291), and 4µg/mL heparin (Sigma-Aldrich H0777).
Mammospheres were grown for 7 days in a 5% CO2 environment. Cells were imaged
using the Leica CTR6500 microscope using AF software after 7 days. The field of view
calculation was determined as follows: each well was divided into 4 quadrants and 3
random images were taken per quadrant for a total of 36 images for each condition to
generate the average number of mammospheres formed for each condition. Experiments
were repeated in triplicate. The average mammosphere diameter (μm) was calculated by
taking the mean of all mammospheres imaged for each condition using ImageJ software.

V.

Western blot analysis
For protein extraction, cell pellets were collected and lysed using lysis buffer (1M

Tris-HCL pH 8.0, 2.5M NaCl, 0.5M EDTA pH 8.0, 2.5mL Triton X-100) supplemented
with protease inhibitors Aprotinin (0.5µL/mL), Leupeptin (1µL/mL), and PMSF
(10µL/mL). Protein lysates were stored at -20°C. A Bradford Assay was performed to
determine protein concentrations. Briefly, a standard curve was generated and
subsequently protein concentrations of samples (5µL sample to 995µL Bradford reagent)
were determined using absorbance readings at 595nm on a spectrophotometer (Biomate 5
Thermo Electron Corporation BIO145108). Protein concentrations were corrected to the
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lysis buffer reading. Samples were prepared using a total of 100 to 150µg of lysate
combined with 4X sample buffer (10% glycerol, 62.5mM Tris-HCL pH 6.8, 2% sodium
dodecyl sulfate (SDS), 0.01mg/mL bromophenol blue, and 2% beta-mercaptoethanol).
Samples were run on a 10% SDS-PAGE page for 3 hours and 30 minutes at 120V (Fisher
Scientfic FB200). Gels were subsequently transferred to a PVDF membrane (Millipore
IPVH00010) for 2 hours 30 minutes at 30V. The membrane required methanol activation
for 1 minute prior to the transfer. Membranes were blocked using 1% BSA (1g of
Albumin Bovine BioBasic Canada Inc. AD0023 in 100mL TBST) for 1 hour on a shaker.
Membranes were incubated with primary antibodies overnight at 4°C rotating constantly.
The following primary antibodies were used: SPDYA (Abcam ab153965), cyclin E
(Abcam ab33911), Numb (Cell Signalling 2756) and Actin Clone C4 (Merck Millipore
mAB1501R). The next day, membranes were washed in 10 minute intervals in TBST for
a total of 3 times. Membranes were submerged in secondary antibodies (anti-mouse IgGPeroxidase and anti-rabbit

IgG-Peroxidase Sigma-Aldrich A9917 and A0545

respectively) diluted in 1% BSA for 1 hour at room temperature while continuously
shaking. Subsequently, membranes were washed again in 10 minute intervals in TBST 3
times. Membranes were imaged under chemiluminescence and densitometry analysis was
performed using FluorChem HD2 imaging software (Alpha Innotech).

VI.

Quantitative real-time polymerase chain reaction (qRT-PCR)
RNA was extracted from samples using a RNeasy Extraction Kit (Qiagen 74134).

Briefly, cells were collected as pellets, lysed and vortexed followed by removal of
genomic DNA. Ethanol was subsequently added to the samples to facilitate RNA binding
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to a RNeasy spin column. Several wash steps were performed and RNA was eluted using
RNase-free water. Concentration and purity were monitored using a NanoDrop
Spectrophotometer (ND-1000 software version 3.3.0 Thermo Scientific). Reverse
transcription of RNA utilized Superscript II reverse transcriptase (Invitrogen 100004925),
0.5µg Oligo dT’s (Eurofin) and 0.5µg random nanomers (Thermo Scientific S0142).
qRT-PCR was run on an ABI Viia7 thermocycler (Applied Biosystems 278880504) using
Fast SYBR green detection (Applied Biosystems 4385616). Reactions were run over the
course of 55 cycles including steps for cDNA denaturation, primer annealing to single
stranded DNA, and elongation. Primers were used at a concentration of 5μM. GAPDH
was used as an internal control. Primers used are listed in Table 3. RNA samples were
stored at -80°C.
VII.

qRT-PCR calculations

Analysis of qRT-PCR reactions was completed using Viia7 software version
1.1.5. Ct values were generated. The Ct value of the gene of interest is normalized to
GAPDH which served as the internal control. This resulted in a ∆Ct value (∆Ct= Ct gene
of interest-Ct GAPDH). The control/calibrator, for example pLKO, is then set to 0 and all
remaining samples are compared to this to generate ∆∆Ct values (∆∆CtshSpy1= ∆CtshSpy1 ∆CtpLKO). The relative quantification (RQ) value is then calculated (RQshSpy1=2-∆∆CshSpy1).
Data is displayed as log10 RQ, representing the fold change between the sample and the
calibrator. Error bars represent the standard error of the average ∆Ct value.
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VIII. Cell surface marker analysis
Detection of fluorescent signals were detected using flow cytometry using the
FL1 (525 BP filter detecting FITC/green) or FL2 (575 BP filter detecting PE/red)
channels. PEIZ over-expression plasmids contain a zsGreen cassette and are detected on
the FL1 channel. For each sample 500 000 cells were collected and stained with
antibodies against CD24-PE (Abcam Inc. ab77219) or CD44-PE (STEMCELL
Technologies Clone IM7 60068PE) for 45 minutes covered on ice. Controls were used to
set up gates prior to running samples (positive control >90% fluorescent in FL2, 0%
fluorescent in FL1). Cells without antibody treatment were used to verify the absence of
non-specific signals. Approximately 200 000 cells were run per reaction. For cells with
Spy1 knock-down, each sample was double-labelled with CD24-FITC (STEMCELL
Technologies Clone 32D12 10424) and CD44-PE covered on ice for 45 minutes.
Following the incubation period, cells were collected by centrifugation at 250 x g for 5
minutes. Cell pellets were then resuspended in 500µl cold 1XPBS and samples were
immediately run on the Beckman Coulter Cytomics FC500 (SYS. ID 469005). Analysis
was completed on CXP Software (Beckman Coulter).

IX.

ALDEFLUOR® Assay
Aldehyde dehydrogenase detection was conducted using the ALDEFLUOR ®

Assay (STEMCELL Technologies 01700). As per the manufacturer’s guidelines 200 000
cells were collected and resuspended in 1mL of ALDEFLUOR® Assay Buffer. For the
negative control, 5µl ALDEFLUOR® DEAB Reagent was added to a 50mL conical tube
and set aside. 5µl of the activated ALDEFLUOR® Reagent was added to the cell
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suspension, mixed thoroughly by pipetting and subsequently 500µl was immediately
transferred to the DEAB-containing control tube. Both the test and the control samples
were incubated at 37°C for 45 minutes. Following the incubation period, cells were
collected by centrifugation for 5 minutes at 250 x g. Cells were resuspended in 500µl
ALDEFLUOR® Assay Buffer and samples were stored on ice until run on the Beckman
Coulter Cytomics FC500. For data acquisition a Side Scatter versus FL1 dot plot was
generated and 100 000 events were collected for each control and test sample using the
same instrument settings.

X.

Statistical analysis
Statistics were performed using a Student’s paired t-test. Data was considered

significant if the p-value was less than 0.05.
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Table 2: Human breast cancer cell lines
Cell line
MDA-MB-231
SK-BR-3
MCF7

Source
ATCC
ATCC
ATCC

Receptor Status
ER-, PR-, HER2ER-, PR-, HER2+
ER+, PR+/-, HER2-

Classification
Claudin-low
HER2
Luminal A

Table 3: Human qRT-PCR primer pairs
Human
Gene
GAPDH

Forward Primer (5’-3’)

Reverse Primer (5’-3’)

GCACCGTCAAGGCTGAGAA
C

GGATCTCGCTCCTGGAAGATG

Spy1

TTGTGAGGAGGTTATGGCCA
TT

GCAGCTGAACTTCATCTCTGTTGT
AG
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RESULTS
I.

Manipulation of Spy1 levels affects mammosphere forming ability
To analyse the effect of elevated Spy1 levels on the relative stem and/or

progenitor population in triple negative breast cancers, Spy1 protein was over-expressed
in MDA-MB-231 and seeded into mammosphere culture (Figure 4). Conditions that
favour the growth of stem-like cells with the ability to self-renew and differentiate were
used106-107. To verify Spy1 levels in the heterogeneous population, western blot analysis
was performed (Figure 4A and 5A). Mammospheres were imaged using bright-field and
fluorescence microscopy to indicate cells were successfully expressing pEIZ and pEIZSpy1 throughout the duration of mammosphere culture (Figure 4B). Results indicate that
Spy1 over-expression significantly increases the number of mammospheres formed by
approximately 18% compared to control conditions (Figure 4C).
Since MDA-MB-231 cells express relatively high levels of Spy1, Spy1 knockdown was performed to test the endogenous significance on mammosphere formation
(Figure 5A and 5B). Infected cells expressing pLKO or pLKO-shSpy1 were grown in
puromycin-containing media for selection. Mammospheres were monitored using brightfield microscopy (Figure 5C) and results reveal that knock-down of Spy1 significantly
decreases the number of mammospheres formed by approximately 26% compared to
control conditions (Figure 5D). Spy1 knock-down did not statistically alter
mammosphere diameter compared to pLKO conditions (Figure 5E). These results
indicate that Spy1 manipulation in some triple negative breast cancer cells affects the
number of mammospheres formed.
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Figure 4. Over-expression of Spy1 increases the number of mammospheres formed.
MDA-MB-231 cells were infected with lentiviral vectors containing pEIZ as a control and
pEIZ-Spy1 to over-express Spy1. Successfully infected cells fluoresce green. (A) Spy1
protein levels were measured using western blot analysis. Actin served as a loading control. (B) Representative microscopy images showing bright-field (left panel) and fluorescent (right panel) images of mammospheres from pEIZ control and Spy1 over-expressing
conditions. Total magnification of 100x. (C) Average number of mammospheres for pEIZ
control and Spy1 conditions was determined using field of view calculation. Error bars
represent standard error of the mean of three independent experiments each counted in
triplicate. *p<0.05. Statistical significance was assessed using a student’s paired t-test.
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Figure 5. Spy1 knock-down decreases the number of mammospheres formed.
MDA-MB-231 cells were infected with lentivirus carrying shRNA against Spy1 (shSpy1)
or a scrambled control (pLKO). (A) Spy1 protein levels were measured using western blot
analysis. Actin served as a loading control. (B) Efficiency of Spy1 knock-down was
assessed using qRT-PCR. Data is normalized to GAPDH and presented as relative quantification (RQ) on a logarithmic scale (log10). Error bars represent standard error of the
mean of two independent experiments run in triplicate qRT-PCR reactions. (C) Representative microscopy images showing bright-field images of mammospheres from pLKO
control and shSpy1 conditions. Total magnification of 100x. (D) Average number of
mammospheres for pLKO control and shSpy1 conditions was determined using field of
view calculation. Error bars represent standard error of the mean of three independent
experiments each counted in triplicate. *p<0.05. (E) Average mammosphere diameter
(µm) for pLKO control and shSpy1 conditions. Mammosphere diameter (µm) was measured using ImageJ software. Error bars represent standard error of the mean of three
independent experiments each counted in triplicate. p>0.05. Statistical significance was
assessed using a student‘s paired t-test.
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II.

Spy1 over-expression increases the number of cells staining positive for
the stemness marker CD44
To assess whether altering Spy1 levels is associated with a change in the relative

stem and/or progenitor population in luminal breast cancers, MCF7 cells were
manipulated to over-express or decrease Spy1 protein levels and subjected to cell surface
marker analysis using the flow cytometer (Figure 6A). Cells successfully expressing
pEIZ and pEIZ-Spy1 emit green fluorescence; hence infection efficiency was also
monitored via flow cytometry (Figure 6B). Labelling for either CD24-PE or CD44-PE
was quantified via flow cytometry analysis (representative profiles Figure 6C). Spy1
over-expression was associated with an approximately 2.5% decrease in staining for
CD24 and a 10% increase in staining for CD44 (Figure 6D). These results were found to
be statistically significant.
Cell populations expressing high levels of CD44 and low levels of CD24 have
been shown to have stem-like properties97,137. Following selection with puromycin, cells
exhibiting successful Spy1 knock-down (Figure 6A) were double-labelled with CD24FITC and CD44-PE and subjected to flow cytometry analysis (representative profiles
Figure 7A). Results indicate that knock-down of Spy1 is associated with an average 14%
decrease in the CD44highCD24low population (Figure 7B).
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Figure 6. Spy1 over-expression increases the number of cells staining positive for the
stemness marker CD44.
MCF7 cells were infected with lentiviral vectors containing pEIZ as a control and pEIZSpy1 to over-express Spy1. (A) Spy1 protein levels were measured using western blot
analysis. Actin served as a loading control. shSpy1 cells are utilized in Figure 7. (B) Successfully infected cells fluoresce green and this was monitored using the FL1 channel
using flow cytometry. (C) Representative flow cytometry plots of either total cell populations (left panel), percentage of cells staining positive for CD24-PE (middle panel), or
percentage of cells staining positive for CD44-PE (right panel) for pEIZ control and Spy1
over-expression conditions. (D) Average percentage of total population staining positive
for CD24 and CD44 for pEIZ control and Spy1 over-expressing conditions. Error bars
represent standard error of the mean of four independent experiments. *p<0.05 **p<0.01.
Statistical significance was assessed using a student’s paired t-test.
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Figure 7. Spy1 knock-down decreases the stem-like CD44highCD24low population.
MCF7 cells were infected with lentivirus carrying shRNA against Spy1 (shSpy1) or a
scrambled control (pLKO). (A) Representative flow cytometry plots showing cells double-labelled with CD44-PE (y-axis) and CD24-FITC (x-axis). Stem-like cells are found in
the CD44highCD24low population (top left quadrant). Percentages indicate the percent
of cells staining positive in each fraction of the total population. (B) Average percentage
of cells of total population staining positive in the CD44highCD24low quadrant for
pLKO control and shSpy1 conditions. Error bars represent standard error of the mean of
four independent experiments. *p<0.05. Statistical significance was assessed using a student’s paired t-test.
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III.

Spy1 knock-down decreases the ALDH positive population in triple
negative and luminal breast cancer cells
As an alternate approach to cell surface marker analysis, the ALDEFLUOR®

assay was utilized to examine the effect of manipulating Spy1 levels on the ALDH
positive cell population in both triple negative (MDA-MB-231) and luminal (MCF7)
breast cancer cell lines. ALDH positive populations are associated with various stem-like
and/or progenitor characteristics118-119. After selection with puromycin, cells successfully
expressing pLKO or pLKO-shSpy1 were incubated with the fluorescent ALDH substrate
and subjected to flow cytometry analysis. MDA-MB-231 cells are known to have an
ALDH positive population8-9,142. To control for background fluorescence, a negative
control using the ALDH inhibitor DEAB was used (Figure 8A left panel). When looking
at the total population, knocking-down Spy1 was associated with an average decrease of
11% in the ALDH positive population in MDA-MB-231 cells (Figure 8B). MCF7 cells
are representative of the luminal subtype of breast cancer and have a relatively small
percentage of ALDH positive cells compared to more aggressive subtypes of breast
cancers like triple-negative breast cancers8-9,142. Compared to the MDA-MB-231
representative flow cytometry profiles showing percentage of cells staining positive for
ALDH in pLKO and shSpy1 conditions, MCF7 cells generally had a smaller percentage
of ALDH positive cells in both conditions (Figure 9A). The trend of decreased Spy1
levels and decreases in the ALDH positive population remained consistent in the MCF7
cells, and was found to be statistically significant (Figure 9B).
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Figure 8. Spy1 knock-down decreases the ALDH positive population in triple negative breast cancer cells.
MDA-MB-231 cells were infected with lentivirus carrying shRNA against Spy1 (shSpy1)
or a scrambled control (pLKO). Cells were monitored for ALDH fluorescence using the
ALDEFLUOR® assay. (A) Representative flow cytometry plots showing percentage of
ALDH positive cells for pLKO control (upper panels) and shSpy1 (lower panels) with
DEAB or without the inhibitor (Test sample). Plots represent ALDH fluorescence
(ALDH) vs. Side Scatter (SS). (B) Average percentage of cells of total population staining
positive for ALDH for pLKO control and shSpy1 conditions. Error bars represent standard error of the mean of three independent experiments. *p<0.05. Statistical significance
was assessed using a student’s paired t-test.
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Figure 9. Spy1 knock-down decreases the ALDH positive population in MCF7 cells.
MCF7 cells were infected with lentivirus carrying shRNA against Spy1 (shSpy1) or a
scrambled control (pLKO). Cells were monitored for ALDH fluorescence using the
ALDEFLUOR® assay. (A) Representative flow cytometry plots showing percentage of
ALDH positive cells for pLKO control (upper panels) and shSpy1 (lower panels) with
DEAB or without the inhibitor (Test sample). Plots represent ALDH fluorescence
(ALDH) vs. Side Scatter (SS). (B) Average percentage of cells of total population staining
positive for ALDH for pLKO control and shSpy1 conditions. Error bars represent standard error of the mean of three independent experiments. *p<0.05. Statistical significance
was assessed using a student’s paired t-test.
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IV.

Spy1 knock-down decreases the stem-like ALDHhigh population in SKBR-3 cells
SK-BR-3 cells are representative of the HER2 expressing subtype of breast cancer

and were one of the original cell lines used to optimize the ALDEFLUOR ® assay143-144.
This cell line is known to contain a substantial ALDHhigh population and is frequently
used as a positive control for this assay143-144. ALDHhigh cells have exhibited stem cell
characteristics in normal mammary development and in breast cancer118-119. To assess
whether altering Spy1 levels is associated with a change in the ALDHhigh population, SKBR-3 cells were manipulated to express decreased levels of Spy1 (shSpy1) compared to
control (pLKO). Efficient knock-down of Spy1 was monitored at the protein level
(Figure 10A); in addition, control and Spy1 infected cells were selected with puromycin.
Flow cytometry analysis revealed a substantial percentage of the total population staining
in the ALDHhigh population (Figure 10B top right panel). Compared to control conditions,
shSpy1 expressing cells exhibited a decrease in the ALDHhigh population, as revealed by
the representative flow profiles (Figure 10B bottom right panel); results revealed shSpy1
expressing cells showed an average 14% decrease in the ALDHhigh population compared
to pLKO expressing cells (Figure 10C). Overall, these results show that Spy1 knockdown decreases the stem-like ALDHhigh population in a cell line representing the HER2+
breast cancer subtype.
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Figure 10. Spy1 knock-down decreases the stem-like ALDHhigh population in SKBR-3 cells.
SK-BR-3 cells were infected with lentivirus carrying shRNA against Spy1 (shSpy1) or a
scrambled control (pLKO). Cells were monitored for ALDH fluorescence using the
ALDEFLUOR® assay. (A) Spy1 protein levels were measured using western blot analysis. Actin served as a loading control. (B) Representative flow cytometry plots showing
percentage of ALDHhigh cells for pLKO control (upper panels) and shSpy1 (lower
panels) with DEAB or without the inhibitor (Test sample). Plots represent ALDH fluorescence (ALDH) vs. Side Scatter (SS). (C) Average percentage of cells of total population
of ALDHhigh cells for pLKO control and shSpy1 conditions. Error bars represent standard error of the mean of three independent experiments. *p<0.05. Statistical significance
was assessed using a student’s paired t-test.
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V.

Knock-down of CyclinE does not cause a significant change in the ALDH
positive population
To test whether decreased levels of other cell cycle regulators such as CyclinE

were associated with a decrease in the ALDH positive population, MDA-MB-231s were
manipulated to express reduced levels of CyclinE (shCyclinE) compared to control
(pLKO). CyclinE was chosen for comparison with Spy1 because they both bind and
activate CDK2 to regulate cell cycle progression. Protein levels of CyclinE were
monitored through western blot analysis to ensure sufficient knock-down (Figure 11A).
Representative profiles reveal similar staining patterns for both control and CyclinE
knock-down conditions (Figure 11B right panel). Quantification of the ALDH positive
population over three replicates revealed a very modest decrease in the ALDH positive
population in the shCyclinE condition (Figure 11C); there was a large amount of
variability over the three replicates and these results did not show statistical significance.
VI.

Over-expression of Spy1 decreases Numb protein levels in triple negative
breast cancer cells
To investigate a potential mechanism for Spy1’s regulatory role in the breast

cancer stem/progenitor populations, Numb protein levels were assessed in control and
Spy1 over-expression conditions in MDA-MB-231 cells (Figure 12A). Numb has a role
in cell differentiation as an inhibitor of Notch signalling; inhibition of the Notch pathway
allows for asymmetric division to occur and subsequent differentiation145-148. Overexpression of Spy1 decreased Numb protein levels in MDA-MB-231 triple negative
breast cancer cells (Figure 12B).
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Figure 11. CyclinE knock-down does not cause a significant change in the ALDH
positive population in triple negative breast cancer cells.
MDA-MB-231 cells were infected with lentivirus carrying shRNA against CyclinE
(shCyclinE) or a scrambled control (pLKO). Cells were monitored for ALDH fluorescence using the ALDEFLUOR® assay. (A) CyclinE protein levels were measured using
western blot analysis. Actin served as a loading control. (B) Representative flow
cytometry plots showing percentage of ALDH positive cells for pLKO control (upper
panels) and shCyclinE (lower panels) with DEAB (left panels) or without the inhibitor
(Test sample; right panels). Plots represent ALDH fluorescence (ALDH) vs. Side Scatter
(SS). (C) Average percentage of cells of total population staining positive for ALDH for
pLKO control and shCyclinE conditions. Error bars represent standard error of the mean
of three independent experiments. p>0.05. Statistical significance was assessed using a
student‘s paired t-test.
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Figure 12. Over-expression of Spy1 decreases Numb protein levels in triple negative
breast cancer cells.
MDA-MB-231 cells were infected with lentiviral vectors containing pEIZ as a control
and pEIZ-Spy1 to over-express Spy1. (A) Numb protein levels were measured using
western blot analysis. Actin served as a loading control. (B) Levels of Numb protein in
pEIZ control and Spy1 over-expression conditions. Densitometry analysis depicts the
average Numb protein levels of two independent experiments, each corrected to the loading control.
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DISCUSSION
Breast cancer is the second leading cause of cancer deaths in Canadian women,
claiming the lives of approximately 14 women each day82. Although advances in earlier
detection and treatment have improved patient outcomes, further understanding the
complex heterogeneity of this disease is critical in improving patient response to therapy
and in the prevention of relapse. Dissecting the roles of different sub-populations found
in breast cancer tumours has revealed aggressive populations with stem cell
characteristics as these cells have been shown to recapitulate tumours in transplantation
experiments97, display increased invasiveness properties138, and exhibit many phenotypic
and functional characteristics similar to normal mammary stem cells24-25,32,95.
Understanding how these populations are regulated is necessary for the development of
targeted approaches in a clinical setting. This work reveals that the atypical cell cycle
regulator Spy1 is involved in regulating the breast cancer stem and/or progenitor
populations found in various breast cancer subtypes.
To investigate if Spy1 regulates breast cancer stem and/or progenitor populations,
Spy1 levels were manipulated in a triple negative breast cancer cell line and subsequently
subjected to in vitro mammosphere assays. MDA-MB-231 cells are known to contain a
sub-population of breast cancer stem cells and endogenously express high levels of
Spy179,142. Over-expressing Spy1 in the cell line revealed an increase in the number of
mammospheres formed. This is consistent with previous findings in the brain showing
Spy1 over-expression increases neurosphere formation. After 7 days in culture,
mammospheres were highly fluorescent, indicating successful lentiviral infection and
high Spy1 expression within the mammosphere structures. To validate these findings, we
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also knocked-down Spy1 expression in MDA-MB-231 cells. A significant decrease in the
number of mammospheres formed was revealed, suggesting a role for Spy1 in the subpopulation of cells involved in mammosphere formation. It has been established that only
cells with stem cell characteristics, mainly the ability to self-renew and give rise to
differentiated cells, are able to form mammospheres in culture106-107. Transcriptional
profiling of mammospheres demonstrated differential gene expression profiles compared
to cells in adherent cultures. Up-regulation of genes required in homing (e.g., CXCR4),
maintaining cells in an undifferentiated state (e.g., IL6), and regulation of self-renewal
(e.g., Wnt pathway) were found in mammopsheres106. Future experiments will look at
potential transcriptional changes within mammospheres when Spy1 is over-expressed.
Previous work has revealed a correlation between mammosphere size and the
ability of mammosphere cells to form tumours in immunocompromised mice, suggesting
that larger mammospheres contain more stem-like cells with the ability to form tumours
when injected into cleared mammary fat pads149. Spy1 knock-down did not significantly
decrease mammosphere size compared to control. This may be due to the observation that
MDA-MB-231 cells normally exhibit variation in mammosphere structure, as opposed to
neurospheres that form uniform spherical multicellular structures, making it challenging
to detect small differences in mammosphere size40,149. To directly assess whether Spy1 is
affecting stem cell self-renewal, a FACS experiment is required, which is an important
future direction for this project. Cells derived from mammospheres that are overexpressing Spy1 can be sorted based on a successfully incorporated green fluorescent tag
into single cell suspension and clonal analysis can be performed. If single cells over-
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expressing Spy1 show an enhanced ability to form multicellular structures in vitro, it
suggests a role for Spy1 in regulating self-renewal parameters.
To further elucidate a potential role for Spy1 in the breast cancer stem cell and/or
progenitor populations, cell surface marker analysis was completed using flow cytometry.
Previous work has revealed a specific cell surface marker phenotype for breast cancer
cells enriched with stem-like characteristics; cells marked with a CD44+/highCD24-/low
phenotype show enhanced mammosphere forming ability, increased invasive properties,
and the ability to recapitulate tumours when transplanted into the cleared fat pads of
immunocompromised mice97,137-138. Spy1 levels were manipulated in MCF7 cells,
representing the luminal A breast cancer subtype8-9. MCF7 cells represent a less clinically
aggressive subtype of breast cancer and have relatively low levels of Spy1 compared to
MDA-MB-231s8-9,87. Cells over-expressing the control pEIZ or Spy1 were tagged with a
fluorescent green marker by lentiviral infection to monitor successful infection over the
course of multiple repeats. To avoid overlap with expression of cell surface marker
antibodies conjugated to green tags, samples were labelled separately with either CD24PE or CD44-PE. Spy1 over-expression significantly increased levels of CD44 and
significantly decreased the levels of CD24 compared to control in MCF7 cells. These
findings suggest a role for Spy1 in regulating the expansion of the CD44+ subpopulation. CD44 plays many important roles in CSCs, aiding in motility, the
maintenance of stemness through ligand-receptor interactions, and drug resistance99,150152

. While CD44 and CD24 are considered standard cell surface markers for identification

of stemness, there is a distinction to be made for separating CD44+CD24- from
CD44highCD24low 139. Both approaches show enrichment for the desired sub-population,
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however cells expressing a CD44highCD24low are thought to contain a higher percentage
of breast cancer stem cells137,139,153-154. Thus, to investigate whether Spy1 alters the
balance of the CD44highCD24low sub-population, Spy1 levels were subsequently knockeddown, cells were double-labelled with CD24-FITC and CD44-PE and subjected to flow
cytometry analysis. Results revealed that Spy1 knock-down consistently decreased the
percentage of CD44highCD24low cells over three repeats, demonstrating a statistically
significant change. This result suggests a role for Spy1 in altering the balance between
breast cancer stem cell enriched versus non-enriched sub-populations. These finding are
consistent with the mammosphere data, further strengthening the support for Spy1’s
potential role in regulating the breast cancer stem/progenitor populations. Sorting cells
expressing a CD44highCD24low phenotype and subsequently subjecting the isolated
population to clonality assays and in vivo transplantation assays will verify that this subpopulation is enriched for breast cancer stem cells97,137, further validating this
experimental model. Manipulating levels of Spy1 within CD44highCD24low expressing
cells will determine the essentiality of Spy1 in this population.
As an alternate method to assess Spy1’s role in regulating breast cancer stem/
progenitor populations, the Aldefluor® Assay was performed; Spy1 levels were
manipulated in MDA-MB-231 and MCF7 cells and the ALDH+ population was
monitored using flow cytometry. It has been previously suggested that cells positive for
ALDH have enhanced stem cell characteristics, both in normal mammary development
and in breast cancer10,118-119. Approximately 16% of MDA-MB-231 control cells were
positive for ALDH (n = 4), consistent with findings in the literature that triple negative
breast cancers have a known ALDH+ population118. Compared to control, Spy1 knock53

down decreased the ALDH+ population to less than 5% on average. This finding, in
conjunction with the mammosphere data using MDA-MB-231s, supports a role for Spy1
in breast cancer stem/progenitor populations. MCF7 cells were also subjected to the
Aldefluor® Assay and control cells had an average lower percentage of cells staining
positive for ALDH compared to MDA-MB-231s. Compared to control, Spy1 knockdown decreased the ALDH+ population by an average 4%, although the change was less
substantial compared to the change seen in MDA-MB-231s. This is expected, as MCF7
cells endogenously have lower levels of Spy1 and are known to contain a comparatively
smaller fraction of breast cancer stem cells142. These results are consistent with the
decrease in the amount of cells staining positive for CD44highCD24low in MCF7 cells with
knock-down of Spy1. Overall these results indicate that cells expressing lower levels of
Spy1 show a significant decrease in the ALDH+ sub-population, known to contain cancer
cells with stem cell characteristics. This effect held true across two different breast cancer
subtypes.
Similar to cell surface marker expression, the literature shows variation in
whether researchers use an ALDH+ phenotype versus an ALDHhigh phenotype. Although
both show enrichment for the breast cancer stem cell sub-population, cells expressing
high levels of ALDH are thought to contain a higher percentage of breast cancer stem
cells10,118. The SK-BR-3 cell line was one of the original cell lines used to optimize the
Aldefluor® Assay for breast cancer samples143-144. SK-BR-3 cells have a known
population of ALDHhigh cells, and can be used as a positive control143-144. SK-BR-3 also
cells have high Spy1 levels, similar to that of MDA-MB-231s. Thus, to investigate
whether Spy1 alters the balance of the ALDHhigh sub-population, Spy1 levels were
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knocked-down in SK-BR-3 cells and the effect on the ALDHhigh sub-population was
assessed using flow cytometry analysis. Knock-down of Spy1 resulted in a significant
decrease in ALDHhigh cells, with an average 10% decrease compared to control cells.
These results further elucidate a role for Spy1 in regulating the stem-like population
found within the ALDHhigh fraction in SK-BR-3 breast cancer cells.
In general, characterizing the stem cell population within breast cancers has been
challenging due to the lack of definitive markers compared to other cancers. For example,
brain tumour-initiating cells can be isolated based on CD133 expression; cells expressing
CD133 can be magnetically sorted and subsequently be subjected to in vitro and in vivo
analysis80. This is in contrast to high/low expression in which magnetic sorting is not
feasible; instead sub-populations need to be carefully gated and sorted based on
fluorescence for precise isolation. When looking at the effect of manipulating Spy1 on
the breast cancer stem/progenitor populations, it was necessary to take multiple
methodological approaches in order to verify the results. Thus, manipulated cell lines
were subjected to mammosphere assays, cell surface marker analysis and the Aldefluor®
Assay; results were therefore corroborated through a variety of different assays,
strengthening support for a potential role for Spy1 in regulating the stem/progenitor
populations in breast cancers. To directly assess whether Spy1 is affecting the breast
cancer stem/progenitor population, it will be necessary to sort the populations and
perform analysis on the isolated population. For example, the ALDHhigh fraction can be
sorted, Spy1 levels can subsequently be knocked-down, and the effect on mammosphere
forming ability can be assessed in vitro, or subjected to in vivo transplantation
experiments. These experiments are part of important future directions for this project.
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Breast cancer is an extremely heterogeneous disease, at both the histological and
molecular levels. The disease is classified into different subtypes, in which a variety of
different breast cancer cell lines exist as representative models8-9,139-140. Three different
breast cancer cell lines were utilized in this study to examine whether Spy1 was an
important regulator across the most prevalent of these subtypes. It was found that
manipulating Spy1 had a significant effect on the relative stem/progenitor populations in
cell lines representing triple negative, luminal, and HER2 over-expressing breast cancers.
Manipulating Spy1 in MDA-MB-231s and SK-BR-3 cells revealed the most substantial
differences when comparing control to experimental conditions. These findings are
consistent with the observation that both of these cell lines have comparatively high
levels of Spy179. Statistically significant differences were also seen in MCF7 cells when
comparing control to experimental conditions, although the differences were more subtle
compared to the other cell lines. These results are consistent with the observation that
MCF7s have comparatively low levels of Spy1. Interestingly, MDA-MB-231s, which
have high levels of Spy1, are clinically very aggressive and typically respond poorly to
conventional therapies94. The poor clinical response may be reflective of expansion of the
breast cancer stem population with enhanced protective mechanisms that are both driving
tumourigenesis and impeding therapeutic response.
Spy1 is an attractive candidate for regulating the growth of the aggressive breast
cancer stem cell population. It has been established in the brain that Spy1 levels are
elevated in clonally derived neurospheres and decrease during stages of differentiation80.
In addition, increased Spy1 levels serve as a block to differentiation and increase the
number and life-span of neural stem/progenitors in culture80. For functional
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differentiation to occur Cdk2 activity must decrease and p27 protein levels must
increase155-156. Spy1 can activate Cdks in an atypical manner and Spy1-Cdk2 complexes
are less sensitive to inhibition by certain CKIs74. In addition, Spy1 can bind and promote
the degradation of p2772,75, which may allow for expansion of the stem cell population
when normally cell cycle progression would be inhibited. Spy1 knock-down, but not
cyclinE knock-down, decreased the ALDH+ population in triple negative breast cancer
cells, suggesting a unique role for Spy1 in regulating the stem-like population. Perhaps
these findings are due to the atypical nature of Cdk activation and ability to promote the
degradation of p27 characteristic of Spy1 that allows for this unique role.
A hallmark characteristic of normal stem cells is the ability to shift between
symmetric and asymmetric division23. Cancer stem cells shift the balance to favour
symmetric division, as it allows for the rapid expansion of the aggressive stem cell
population in tumours23. In BTICs, Spy1 demonstrated an important role in maintaining
symmetric division, as revealed through Numb distribution assays80. Numb’s primary
role in cell differentiation is as an inhibitor of Notch signalling; inhibition of the Notch
pathway allows for asymmetric division to occur and subsequent differentiation145-147.
When the protein Numb is distributed unevenly throughout a cell, this promotes
asymmetric division because it influences the response of the daughter cells to Notch
signaling, yielding two distinct cell fates145. Numb can be repressed at a translational
level by Musashi-1 (Msi1); this allows for activation of Notch signalling in the absence
of the inhibitor Numb (Figure 13)157. Interestingly, Spy1-CDK signalling has been shown
to activate Musashi-1 (Msi1)157. Spy1-CDK activation of Msi1 may serve as a
mechanism for Spy1’s potential regulatory roles in the breast cancer stem/progenitor
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Figure 13: Potential mechanism for Spy1’s regulatory role in the breast
cancer stem and/or progenitor populations
Spy1-CDK signalling has been shown to activate Musashi-1. Numb can be
repressed at a translational level by Musashi-1157; this allows for activation of Notch
signalling in the absence of the inhibitor Numb145-147. Notch signalling is an important
pathway regulating self-renewal decisions and thus contributes to the maintenance of
stem and progenitor populations43, 51-53.
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populations. Preliminary data reveal that over-expression of Spy1 in the heterogeneous
population of triple negative breast cancer cells correlate with a decrease in Numb protein
levels. The connection between Spy1 and Numb will be further probed in cell sorted
populations to investigate the potential mechanism for regulation.
This is the first study to investigate the potential role of Spy1 in stemness
properties in breast cancer.

In summary, over-expression of Spy1 increases the

mammosphere forming ability of breast cancer stem/progenitor cells and increases
overall levels of the stemness marker CD44; similarly, knock-down of Spy1 decreases
the number of mammospheres formed, and decreases the CD44highCD24low, ALDH+, and
ALDHhigh sub-populations (Table 4). Collectively, these findings provide strong support
that Spy1 plays a regulatory role in breast cancer stem and/or progenitor populations. The
cancer stem cell model has important clinical implications and understanding the
different sub-populations driving tumourigenesis is crucial to the development of targeted
clinical approaches (Figure 14)30,32,95. Dissecting the key regulators of the most
aggressive breast cancer stem and/or progenitor populations will aid target-specific
approaches, ultimately improving patient outcome. The findings in this study may have
clinical implications toward targeted approaches in the treatment of breast cancer.
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Table 4: Effect of Spy1 on the relative stem cell population within various breast
cancer cell lines
Breast cancer
cell line

CD44highCD24low ALDEFLUOR
cell surface
ASSAY®
marker analysis
Spy1= CD44
Spy1=
staining
ALDH+
population
Spy1 =
CD44highCD24low
population

Relative
Spy1
levels79
low

Mammosphere
assay

SK-BR-3
HER2 Positive

high

-

-

MDA-MB-231
Claudin-Low

high

Spy1=
number of
mammospheres

-

MCF7
Luminal A

-

Spy1= number
of
mammospheres

Spy1=
ALDH+
population
Spy1=
ALDH+
population
CyclinE = no
change ALDH+
population
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Figure 14: The significance of cancer stem cell directed targeting strategies
Cancer stem cells (yellow), compared to more differentiated cells (blue, orange, red),
have enhanced protective mechanisms that make them resistant to conventional therapies
and may be responsible for relapse30,32,95. Designing treatment options to target this
aggressive population by elimination or coaxing them to a more differentiated state may
aid in complete remission after treatment.
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